Rapid developments in healthcare and drug discovery sector are leading to the introduction of new therapeutic solutions for the treatment of neurological diseases. Authorities such as World Health Organization, National Institute of Neurological Disorders and Stroke, and National Institutes of Health are taking constructive steps to encourage the research activities and find a remedy for neurological disease treatment.

Download sample PDF Brochure Here

A biomarker is an indicator of normal biological processes, pathogenic processes, or evaluating a therapeutic intervention. Thus, the discovery of biomarker is an active research area, where a few biomarkers have been sufficiently studied and validated for its use in clinical practice and clinical trials.

The National Institute of Neurological Disorders and Stroke (NINDS) biomarker program is focused on enhancing the quality and efficiency of neurotherapeutic clinical research and supports the biomarker validation. The program promotes rigorous biomarker identification and validation by providing funds for the research activities. Similarly, Parkinson’s Disease Biomarkers Program (PDBP) was initiated to support new and existing research promoting the discovery of biomarker for Parkinson's disease.

Based on product, the global neurological biomarker market is segmented into proteomics biomarker, genomics biomarker, metabolomics biomarker, imaging biomarker, and others. In 2019, the genomic biomarkers held the largest share of the market, and the market for the same is expected to grow at the fastest CAGR during the forecast period. This lucrative growth of the market for genomic biomarkers is attributed to increasing awareness among consumers regarding the benefits of genetic medicines as well as technological advancements in the field of neurological biomarkers. In addition, the shift in preference toward gene counseling and genetic analysis for diagnostic purposes is also likely to fuel the growth of the segmental market. The genetic biomarkers are significant modalities that directs toward a more personalized approach for predispositions and medical analysis.

The global neurological biomarker market, based on application,is segmented into Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's disease, spinal muscular atrophy, and others. The Alzheimer's diseasesegment held the greatest share of the market in 2019. Moreover, it is also estimated to register the highest CAGR in the marketduring 2020–2027.

Source: The Insight Partners

Rise in prevalence of neurological disorders like Alzheimer's, Parkinson's, Epilepsy, across the world, and high rate of diagnosis and treatment of frontotemporal dementia, and other neuro-stimulation diseases are the critical factors driving the brain pacemaker market globally in the study period.

Download sample PDF Brochure of Study, Click Here

A brain pacemaker is an electrical device, which stimulates an electrical beat to the heart if there is an arrhythmia (irregular heartbeat). It is an electrical machine (also known as wireless artifact-free neuromodulation device), which sends electrical stimulation if there is an irregular electrical activity in the brain. The device is autonomous and wireless, which means once the device learns to identify the signs of seizures (or other improper electrical activities in the brain), it can regulate the stimulation parameters on its own to resist the irregular electrical movements of the brain.

Also, the device is closed-loop and can deliver electrical signal and record electrical activities of the brain simultaneously and regulate the stimulation parameters in real-time. Customized integrated circuits in the device can record the full message from the brain waves and electrical pulses. Additionally, the device can record electrical activities of the brain over 128 channels or from 128 points located in the brain, while other closed-loop systems can measure electrical activities of the brain over eight channels.

Key Trends

• According to the Centers for Disease Control and Prevention (CDC), around 1.3% of the population of the U.S. suffered from active epilepsy, and 0.02% of the population was diagnosed with Parkinson's disease in 2017.
• The cost for devices and surgery can range from $35,000 to $100,000 and is typically covered by private insurance and Medicare because of FDA approval in developed countries.
• The FDA has been working with neurological device manufacturers and professional societies such as NeuroPoint Alliance and NIH (Stroke Net) to facilitate the development of robust registries that will help with post market surveillance.
• This system, with the Vercise Cartesia Directional Lead, is designed to treat the symptoms of Parkinson's Disease by delivering the specific targeted electrical stimulation in the brain to provide optimal symptom relief and better control of unwanted side effects

Followings are the key companies operating in this research are Abbott, ALEVA NEUROTHERAPEUTICS SA, Beijing PINS Medical Co., Ltd., Boston Scientific Corporation, INNOVATIVE NEUROLOGICAL DEVICES, LivaNova PLC, Medtronic, NeuroPace, Inc., Nexeon MedSystems Inc., Zynex Medical

Source: The Insight Partners